Aspirin-free antiplatelet regimens after PCI: insights from the GLOBAL LEADERS trial and beyond.

Wang, Rutao; Wu, Sijing; Gamal, Amr; Gao, Chao; Hara, Hironori; Kawashima, Hideyuki; Ono, Masafumi; van Geuns, Robert-Jan; Vranckx, Pascal; Windecker, Stephan; Onuma, Yoshinobu; Serruys, Patrick W; Garg, Scot (2021). Aspirin-free antiplatelet regimens after PCI: insights from the GLOBAL LEADERS trial and beyond. European heart journal. Cardiovascular pharmacotherapy, 7(6), pp. 547-556. Oxford University Press 10.1093/ehjcvp/pvab035

Preview

Text Aspirin-free.pdf - Published Version Available under License Creative Commons: Attribution-Noncommercial (CC-BY-NC). Download (959kB) | Preview

Historically, aspirin has been the primary treatment for the prevention of ischaemic events in patients with coronary artery disease. For patients undergoing percutaneous coronary intervention (PCI) standard treatment has been 12 months of dual antiplatelet therapy (DAPT) with aspirin and clopidogrel, followed by aspirin monotherapy; however, DAPT is undeniably associated with an increased risk of bleeding. For over a decade novel P2Y12 inhibitors, which have increased specificity, potency, and efficacy have been available, prompting studies which have tested whether these newer agents can be used in aspirin-free antiplatelet regimens to augment clinical benefits in patients post-PCI. Among these studies, the GLOBAL LEADERS trial is the largest by cohort size, and so far has provided a wealth of evidence in a variety of clinical settings and patient groups. This article summarizes the state-of-the-art evidence obtained from the GLOBAL LEADERS and other trials of aspirin-free strategies.

Interest & Impact

Downloads

91 since deposited on 20 Jan 2022
50 in the past 12 months

Citations

5 Citations in Web of Science ®
6 Citations in Scopus

Search

in Google Scholar™

Services

Actions (login required)

Edit item

Actions (login required)

Edit item